On July 23, MEDBOT-B rose 10.72% in regular trading, trading at 23.9 HKD/share, with turnover of HKD 62.26 million. The surge was driven by the company's positive profit alert released on July 22.

According to the announcement, the company expects net profit of RMB 28 million to RMB 40 million for the six months ended June 30, compared to a net loss of RMB 115 million in the same period last year, marking the company's first-ever half-year profitability. Revenue is expected to grow approximately 200% to 230% year-over-year. The core product Toumai laparoscopic surgical robot expanded significantly in both domestic and overseas markets, with overseas market revenue surging over 450% year-over-year. Additionally, Toumai's remote surgery full-department application has obtained EU CE certification, becoming the world's first approved remote surgical robot. The company has achieved over 300 global commercial orders and completed 200 commercial installations across more than 60 countries and regions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)